Investigation of plaque psoriasis relapse after secukinumab withdrawal in patients from two phase III studies
Clinical and Experimental Dermatology2023Vol. 49(8), pp. 793–800
Citations Over TimeTop 10% of 2023 papers
Mark Lebwohl, Lars Iversen, Liv Eidsmo, James G. Krueger, Mayte Suárez‐Fariñas, Lewis E. Tomalin, Frank Kolbinger, R. You, M. Milutinovic
Abstract
Following discontinuation of secukinumab, a proportion of patients stayed relapse-free. Further, patients with shorter disease duration remained relapse-free for longer, suggesting that earlier treatment with secukinumab may result in long-term clinical control of moderate-to-severe PsO.
Related Papers
- → Efficacy of secukinumab without the initial weekly loading dose in patients with chronic plaque psoriasis(2019)12 cited
- → Drug survival of secukinumab for moderate-to-severe plaque psoriasis(2018)6 cited
- → Drug survival of secukinumab for moderate-to-severe plaque psoriasis: reply from authors(2018)1 cited
- → Cost-utility of secukinumab in Italian patients with moderate to severe plaque-type psoriasis(2017)
- → Outcomes With Treatment and Withdraw of Secukinumab in Patients With Plaque Psoriasis(2020)